# AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct06951503/  
OnCo record `nct06951503` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Oxaliplatin and Bevacizumab in colorectal cancer, run by Akeso, now recruiting.

## Summary

AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT06951503 by Akeso, with 560 participants planned, started 2025-05-27 and due to reach its primary completion in 2027-01-13. Interventions recorded: AK112, Oxaliplatin, Irinotecan, Leucovorin and 5-FU and Bevacizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06951503
- Phase: 3
- Setting: A Randomized, Controlled, Multicenter Phase III Clinical Study of AK112 Combined With Chemotherapy Versus Bevacizumab Combined With Chemotherapy in First-line Metastatic Colorectal Cancer
- Sponsor: Akeso
- Enrolled: 560

## Sources

- ClinicalTrials.gov NCT06951503: https://clinicaltrials.gov/study/NCT06951503

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct06951503.json